Home > Gastroenterology > ECCO 2022 > Short-Term and Long-Term Treatment Results > Stopping infliximab but not antimetabolites leads to more relapses in Crohn’s disease

Stopping infliximab but not antimetabolites leads to more relapses in Crohn’s disease

Presented By
Prof. Edouard Louis, University Hospital Liège, Belgium
Conference
ECCO 2022
Trial
Phase 4, SPARE
In patients with Crohn’s disease (CD) who achieved sustained remission on infliximab plus antimetabolite therapy, infliximab discontinuation was associated with an increased risk of relapse in the phase 4 SPARE trial. In contrast, antimetabolite discontinuation did not lead to significantly higher relapse rates compared with continuation of the combination treatment. Since physicians often contemplate de-escalation of infliximab plus antimetabolite therapy, these results may inform the decision-making process of treatment de-escalation in patients with CD. “Infliximab in combination with antimetabolite therapy is a standard option for patients with CD,” explained Prof. Edouard Louis (University Hospital Liège, Belgium) [1]. “Clinicians may contemplate de-escalation of this therapy if sustained remission is achieved.” The current, prospective, randomised-controlled, phase 4 SPARE trial (


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on